Lassen Therapeutics develops fully human monoclonal antibodies targeting the interleukin-11 receptor to treat fibrotic diseases such as thyroid eye disease and idiopathic pulmonary fibrosis. Their approach aims to inhibit IL-11 signaling, addressing the underlying mechanisms of fibrosis to improve patient outcomes.
Funding
$117M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FLFounders
Product
Problem
Fibrotic diseases, such as thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF), lead to significant morbidity and mortality. Current treatments often fail to address the underlying mechanisms driving fibrosis, resulting in limited efficacy and suboptimal patient outcomes.
Solution
Lassen Therapeutics is developing fully human monoclonal antibodies that target the interleukin-11 receptor (IL-11R) to treat fibrotic diseases. Their lead program, LASN01, inhibits IL-11 signaling, a central mediator of fibrosis, thereby addressing the root cause of these diseases. By blocking the IL-11 pathway, Lassen's approach aims to prevent and reverse fibrosis, offering a potential new therapeutic option for patients with TED and IPF. The company is also developing LASN500, with ongoing Investigational New Drug (IND) enabling studies.
Target Audience
The primary target audience includes patients suffering from fibrotic diseases such as thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF).
Features
- Fully human monoclonal antibodies with high affinity and specificity for IL-11R
- LASN01: Clinical-stage antibody currently in Phase 2 study for thyroid eye disease (TED)
- LASN500: Antibody in Investigational New Drug (IND) enabling studies
- Designed to potently block IL-11 signaling and prevent IL-11 driven fibrotic diseases